In-depth Analysis of the COVID-19 Impact on Global In Vivo Toxicology Market 2022

Growth Factors Driving the Market: The In Vivo Toxicology Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine

MarketsandMarkets™ View on Revenue: The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period.

Industry Segmentation in Detailed:

The immunotoxicity segment accounted for the largest share of the in vivo toxicology market.

Based on toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment

The chronic test type segment accounted for the largest share of the in vivo toxicology market.

Based on test type, the global in vivo toxicology testing market is segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.

The outsourced testing facilities segment accounted for the largest share of the in vivo toxicology market.

Based on the testing facility, the global in vivo toxicology market is segmented into outsourced testing facilities and in-house testing facilities. The outsourced testing facilities segment is expected to dominate the market, by testing facility, over the forecast period. In 2019, the outsourced testing facilities segment held the largest share of the global in vivo toxicology market. The large share of this segment is attributed to the increasing R&D investments and cost-saving strategies of pharmaceutical, biopharmaceutical, and medical devices companies, resulting in increased outsourcing of services to CROs

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811

Leading Key Players Analysis:

The major players operating in In Vivo Toxicology Testing Market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others.

 

Geographical Trends in Detailed:

The global in vivo toxicology market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

 

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811

Contract Research Organization Services Market - Emerging Industry Trends and Global Future Forecast

Growth Factors Driving the Market: The Growth in CRO services market can mainly be attributed to factors such as the increasing investment in pharmaceutical R&D, rising number of clinical trials, high cost of in-house drug development (encouraging pharma-biotech companies to opt for outsourcing), and the rising prevalence of orphan and rare diseases (creating new revenue pockets for CROs). Growth in the drugs and biologics market despite the COVID-19 pandemic, the increasing demand for specialized testing services among end users, and the need for novel clinical trial designs for complex cell and gene therapies are also expected to offer a wide range of growth opportunities to players operating in this market.

MarketsandMarkets™ View on Revenue: The Global Contract Research Organization (CROs) Services Market is estimated to grow from USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0% during the forecast period.

Industry Segmentation in Detailed:

The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2021.

Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.

The oncology subsegment accounted for the largest share of the therapeutic area segment in the CRO services market in 2021.

Based on therapeutic area, the CRO services market is segmented into oncology, infectious diseases, neurology, vaccines, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the global CRO services market in 2021. The large share of this segment is primarily attributed to the increasing number of drug discovery activities for oncology and the rising prevalence of cancer worldwide.

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167410116

Leading Key Players Analysis:

The Asia Pacific region is the fastest-growing region of the CRO services market.

 

Key players in the global CRO servicesMarket include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (a part of Thermo Fisher Scientific, Inc.), ICON plc (Ireland), Charles River Laboratories International, Inc. (US), WuXiAppTec Co., Ltd. (China), Syneos Health Inc. (US), Parexel International Corporation (US).

 

Geographical Trends in Detailed:

The global CRO services market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The market in the Asia Pacific is estimated to record the highest CAGR during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, increasing number of pharmaceutical companies establishing their manufacturing facilities in the region, and the lower cost of clinical trials in the region.

 

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=167410116

Cancer Diagnostics Market - Growth and key Players Analysis and Forecast

Growth Factors Driving the Market:  The Growth of the Cancer Diagnostics Market is driven mainly by increasing incidence of cancer and growth in the number of private diagnostic laboratories.

In an attempt to detect cancer in the early stages and bring down the mortality rate, governments in developed countries and primary care doctors are recommending cancer screening tests for patients. The US Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer starting at 50 years of age to 75 years of age in the US as a means of preventing disease incidence and ensuring early-stage treatment. Canada has also implemented guidelines for biennial colorectal cancer screening for people aged 50 to 74 years.

MarketsandMarkets™ View on Revenue: The global cancer diagnostics market size was valued at USD 17.2 billion in 2021 and is expected to grow at a CAGR of 11.5%

Industry Segmentation in Detailed:

The consumables segment is expected to grow at the highest CAGR during the forecast period.

Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to witness the highest growth during the forecast period. The repeated purchase and high consumption, and the high prevalence of diseases the major factors supporting the growth of this segment.

The technology segment accounted for the largest share of the cancer diagnostics market.

By technology, the cancer diagnostics market is segmented IVD testing, imaging based and biopsy technique. The IVD testing segment accounted for the largest market share in 2020. The large share of this segment can be attributed to increasing incidence of cancer.

Hospitals for the largest share of the cancer diagnostics market.

Based on end-users, the cancer diagnostics market is segmented into hospitals and diagnostic laboratories. The hospitals segment accounted for the largest share of the cancer diagnostics market in 2020. The increasing number of patients visiting hospitals, rising number of in-house diagnostic procedures performed in hospitals, and growing awareness regarding early diagnosis is are the major driving factor for this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121

Leading Key Players Analysis:

Some of the major players operating in this market are GE Healthcare (US), Roche Diagnostics (Switzerland), and Becton, Dickinson and Company (US). In 2020, GE Healthcare held the leading position in the market. The company has a strong geographic presence across the US, Asia, Europe, Middle East and Africa, & the Americas. Moreover, the company’s strong brand recognition and comprehensive product portfolio in the cancer diagnostics market is its key strength. BD held the second position in the cancer diagnostics market in 2020.

Geographical Trends in Detailed:

The cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest share of the cancer diagnostics market. The large share of North America can be attributed to factors such as the increasing incidences of cancer, growing awareness early diagnosis and technological advancement.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121

Aptamers Market - Developing Regions is Well-Positioned for Strong Growth in the Coming Years

Growth Factors Driving the Market: The Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.

MarketsandMarkets™ View on Revenue: The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.

Industry Segmentation in Detailed:

“The therapeutics development segment will continue to dominate the aptamers application market during the forecast period”

Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.

"Pharmaceutical & biotechnology companies are the largest end users of aptamers technology"

Based on end user, the global aptamers market is segmented into pharmaceutical companies & biotechnology companies, academic & government research institutes, contract research organizations, and other end users. In 2020, pharmaceutical & biotechnology companies dominated the market owing to the increasing number of market players offering custom aptamers for use in therapeutics development & rising R&D expenditure. The diagnostic segment will record the highest CAGR during the forecast period due to the development of diagnostic tools for cancer and infectious diseases.

“The DNA-based aptamers segment will continue to dominate the aptamers type market during the forecast period"

Based on type, the aptamers market is segmented into DNA aptamers, XNA aptamers, and RNA aptamers. The DNA-based aptamers segment dominated the market in 2020. The large share of this segment is attributed to their lower production cost and higher stability compared to other nucleic acid-based aptamers and the wide availability of DNA aptamers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167

Leading Key Players Analysis:

Some of the key players operating in the aptamers technology market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain), Base Pair Biotechnologies (US), AMSBIO (UK), Novaptech (France), Bio-Techne (US) among others.

Geographical Trends in Detailed:

The global aptamers market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of this market. The largest share of North America is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies. The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rising R&D activities on aptamers, the development of aptamer-based products, and the rising focus on drug discovery and development.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1167

Veterinary Equipment and Disposables Market - In Depth Analysis of Industry Segments, Growth Drivers and Key Players

According to a new market research report “Veterinary Equipment and Disposables Market by Product (Consumables, Anesthesia Machines, Ventilators, Patient Monitoring, Oxygen Masks, Infusion Pumps), Animal (Cats, Dogs, Equines, Bovines), End User (Hospitals, Clinics) – Global Forecast to 2023″, published by MarketsandMarkets™, the global Veterinary Equipment Market is projected to reach USD 2.40 billion by 2023 from USD 1.63 billion in 2018, at a CAGR of 8.0% during the forecast period of 2018 to 2023.

The Veterinary equipment and disposables are used in monitoring, surgeries, and the treatment of diseases in animals. Rising animal health expenditure and growing demand for pet insurance, increasing number of veterinary practitioners in developed regions, and growth in the companion animals market are the primary drivers for the global veterinary equipment market and veterinary disposables market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14169630

Growth in the companion animal population;

The adoption of companion animals has grown globally due to the positive health benefits associated with them—reduced cardiac arrhythmias, normalization of blood pressure, decreased anxiety, greater psychological stability, and improved wellbeing. According to the APPA National Pet Owners Survey 2017–2018, the canine population in the US increased from 69.9 million in 2012 to 89.7 million in 2016, while the feline population increased from 74.05 million in 2012 to 94.2 million in 2016. According to the European Pet Food Industry Federation (FEDIAF), the canine population in Germany increased from 5.30 million in 2012 to 8.66 million in 2016, whereas the feline population increased from 8.20 million in 2012 to 13.40 million in 2016.

Emerging markets such as Brazil, China, India, and Mexico are also witnessing growth in animal ownership. According to the India International Pet Trade Fair (IIPTF), the number of pets increased from 11 million in 2014 to 15 million in 2016. Approximately 600,000 pets are adopted every year in India. Such trends are expected to support the growth of the animal health industry, which, in turn, will drive the growth of dependent industries such as veterinary equipment market and veterinary disposables market.

The critical care consumables segment is expected to account for the largest share of the Veterinary Equipment and Disposables Market in 2018. 

On the basis of type, the critical care consumables segment accounted for the largest share of the global Veterinary Equipment and Disposables Market. The large share of consumables can be attributed to the large number of consumables required and consumed in almost every veterinary care process, as opposed to the one-time cost of capital equipment.

The small companion animals will continue to dominate the Veterinary Equipment and Disposables Market during the forecast period.

Based on animal, the small companion animals’ segment will dominate the Veterinary Equipment and Disposables Market in 2023. The large share of this segment can be attributed to the high adoption of companion animals and rising expenditure on animal health.

The veterinary clinics segment is estimated to hold the largest market share of the Veterinary Equipment and Disposables Market in 2023.

Based on end user, veterinary clinics are estimated to hold the largest share of the Veterinary Equipment and Disposables Market in 2023. The large share of this segment can be attributed to the growing number of patient visits along with the increasing number of private clinical practices and increasing practice revenues.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=14169630

North America will dominate the market in 2023. 

North America is estimated to hold the largest share of the Veterinary Equipment and Disposables Market during the forecast period, followed by Europe and the Asia Pacific. Factors such as the increasing number of companion animals, rising companion animal healthcare expenditure, rise in the number of livestock animals in North America (primarily due to the increasing consumption of meat and dairy products), and growth in the pet insurance market are responsible for the region’s large share in the global Veterinary Equipment and Disposables Market.

The prominent players in the Veterinary Equipment and Disposables Market are Mindray Medical International Limited (China), Smiths Group plc (UK), Nonin Medical (US), Digicare Biomedical Technology, Inc. (US), B. Braun Melsungen AG (Germany), Henry Schein (US), Vetland Medical Sales and Services, LLC (US), Hallowell Engineering & Manufacturing Corporation (US), Infiniti Medical, LLC (US), DRE Veterinary (US), and Midmark Corporation (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=14169630

Global Back-end Revenue Cycle Management Market Trends and Industry Analysis Report

The research report "Back-End Revenue Cycle Management Market by Product and Services (Claim Processing, Denial Management, Payment Integrity), Delivery Mode (On-Premise, Cloud Based), End-User (Payer, Provider (Inpatient, Outpatient)), and Region - Global Forecast to 2027", is projected to reach USD 12.2 billion by 2027 from USD 8.6 billion in 2019, at a CAGR of 4.4%.

Growing importance of denials management;

To reduce costs and maximize profits, insurance companies are increasingly denying claims as well as coverage to patients being treated for chronic or persistent illnesses. This is putting an extra burden on healthcare providers to manage operating costs, and in turn is supporting the adoption of back-end revenue cycle management solutions (with a growing number of healthcare providers focusing on properly analyzing denied claims and appealing them).

Many healthcare providers across the globe still use manual and paper-oriented approaches to manage denials. This results in errors, delayed follow-ups, and miscommunication between healthcare providers and insurance companies. The use of back-end revenue cycle management solutions over manual and paper-oriented approaches can not only help healthcare providers overcome these issues but also help them save significant costs. As a result, the demand for back-end revenue cycle management solutions is expected to increase among end users during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=204439794

Leading Key Players and Analysis:

Athenahealth (US), Cerner Corporation (US), Allscripts Healthcare Solutions, Inc. (US), eClinicalWorks (US), Optum, Inc. (US), McKesson Corporation (US), Conifer Health Solutions (US), GeBBs Healthcare Solutions (US), The SSI Group (US), GE Healthcare (US), nThrive (US), DST Systems (US), Cognizant Technology Solutions (US), and Quest Diagnostics (US) are the key players in the Back-End RCM Market.

Cerner has a strong foothold in the back-end revenue cycle management market. The company caters to the healthcare technology and financial management needs of its global customers. Cerner focuses on research and development activities, deploying products, and acquisitions to enhance its market presence. For instance, in the past three years, the company deployed more than 15 back-end revenue cycle management solutions across various hospitals, care centers, and medical centers. The acquisition of Siemens Health Services in January 2015 further strengthened its back-end revenue cycle management portfolio.

Geographical Analysis in Detailed?

The back-end revenue cycle management market is divided into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in 2018 owing to factors such as growing HCIT investments in the region and the presence of regulatory mandates. North America is followed by Europe and Asia. The market in Asia is relatively nascent; however, it is projected to be the fastest-growing market during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=204439794

Industry Segmentation:

The Services segment to dominate the back-end revenue cycle management market.

By product & service, segmented into software and services. The services segment is expected to account for the largest share of the Back-End RCM Market in 2018. The large share of this segment can be attributed to the recurring nature of services such as training and development, installation, software upgrades, consulting, and maintenance. However, due to the need for periodic software upgrades, the software segment is expected to witness the highest growth during the forecast period.

The cloud-based systems to register the highest CAGR during the forecast period

On the basis of delivery mode, segmented into on-premise and cloud-based systems. The cloud-based segment is expected to register the highest CAGR of the back-end revenue cycle management market during the forecast period. Growth in this segment can be attributed to the comparatively lower capital expenses and operational costs incurred in this model, alongside its scalability, flexibility, and affordability.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=204439794

Orthodontic Supplies Market - Growth by Top Key Players, Application and Forecast Analysis

According to the new market research report “Orthodontic Supplies Market by Product (Braces (Removable, Fixed), Brackets (Ligating, Lingual, Metal), Archwires (Ni-Ti, steel), Anchorage, Ligature(Elastomeric, wire), Patient(Adult, Children), Users(Hospitals, Clinics, OTC) – Global Forecast to 2026″, published by MarketsandMarkets™, the Orthodontic Products Market is projected to reach USD 8.3 billion by 2026 from USD 5.4 billion in 2021, at a CAGR of 9.1% during the forecast period.

Opportunity: Emerging markets in APAC and RoW;

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the orthodontic supplies market. Growth in these markets can be attributed to the presence of a large patient population, rising disposable incomes among the middle-class population, and the increasing focus of public and private organizations on increasing the awareness about orthodontic treatments and dental hygiene. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers.

Along with this, many players are focusing on strategic investments to develop end-to-end digital software solutions with 3D digital scanning, diagnostics, outcome visualization, treatment planning, custom appliances, and custom lab products. For instance, in September 2020, Light Force Orthodontics, a manufacturer of customizable 3D-printed bracket systems, raised USD 14 million from Series B round led by Tyche Partners with follow-on investment from Matrix Partners and AM Ventures.

This 3D printing technology helps to create customized braces for each patient. This plays a critical role in significantly reducing the number of visits to orthodontic clinics for the adjustment of braces. These developments are expected to provide a wide range of opportunities for players to capture a large customer base in the orthopedic supplies market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=236529189

The Increasing prevalence of malocclusion, rising emphasis on effective orthodontic treatment and t the initiatives undertaken by governments to increase the awareness about orthodontic treatments are fueling the demand for orthodontic supplies during the forecast period.

The orthodontic supplies market includes major Tier I and II suppliers of orthodontic products are 3M (US), Envista Holdings Corporation (US), Dentsply Sirona (US), Align Technology (US), American Orthodontics (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), Morelli Orthodontics (Brazil), ClearCorrect (US), and Ultradent Products (US).

These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Due to the pandemic, the orthodontic supplies market experienced short-term negative growth, which can be attributed to a sharp reduction in access to hospital and dental clinics and the temporarily shutdown of orthodontic clinics.

Orthodontic practices around the globe are facing challenges amid the pandemic. The adoption of strict protocols outside and inside dental clinics, increasing usage of teleorthodontics in case of urgent appointments, and opting for minimal orthodontic treatment procedures by many orthodontic clinics are likely to have a positive impact on the market. Moreover, post lockdown, as dental practices reopen, it is expected that patient volumes are anticipated to rebound at a higher pace.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=236529189

Demand for invisible braces among the target population due to their aesthetic benefits drives the growth of removable braces

Removable braces offer advantages over traditional braces, including easy removal of braces, reduced risk of periodontal diseases & tooth decay, and enhanced comfort. Factors such as strong focus on product innovation by players and growing awareness about the benefits associated with removable braces and the growing demand for invisible braces among teens and adults due to their aesthetic benefits is augumenting the growth of removable braces.

Asia Pacific likely to emerge as the fastest growing orthodontic supplies market, globally

Geographically, the emerging Asian countries, such as China, India, Japan and Singapore, are offering high-growth opportunities for market players. The Asia Pacific point of care market is projected to grow at the highest CAGR of 10.8% from 2021 to 2026. Expansion of healthcare infrastructure and increase in disposable personal income, increase patient population with malocclusion and tooth decay are factors likely to support the growth of market in the region. Moreover, the growing focus toward aesthetics products among adults and emergence of small manufacturers in the market are driving the growth of the APAC orthodontic supplies market.

Prominent players in this market are 3M (US), Envista Holdings Corporation (US), Dentsply Sirona (US), Align Technology (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), among others.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=236529189

Hernia Repair Market Analysis 2022 - Globally by Key Manufacturers, Countries, Type, Application and Forecast

According to the new market research report “Hernia Repair Market by Product (Mesh (Synthetic, Biologic), Mesh Fixation (Suture, Tack and Glue Applicator)), Surgery Type (Inguinal, Incisional/Ventral, Umbilical, Femoral), and Geography (America, Europe, Asia Pacific) – Forecast to 2023″, published by MarketsandMarkets™, the hernia mesh market is projected to reach USD 4.75 Billion by 2023 from USD 4.09 Billion in 2018, at a CAGR of 3.0% during the forecast period.

Recent Developments:

– In 2017, BD acquired C. R. Bard. With this acquisition, BD entered the hernia repair business. The acquisition is expected to help C. R. Bard to increase its geographic presence in terms of both—sales and operations and maintain its market position.

– In 2017, Allergan acquired LifeCell Corporation. This acquisition expanded its medical aesthetic products portfolio by the addition of ALLODERM and STRATTICE.

– In June 2017, W. L. Gore GORE launched SYNECOR Preperitoneal Biomaterial. The newly launched product helped the company to broaden its product offerings in the hernia market

– In 2016, B. Braun opened its new subsidiary in Zambia named ‘B. Braun Medical Zambia Limited’ which will help the company to establish a strong foothold in Southern Africa.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203245450

The rising adoption of mesh in hernia repair surgeries, rising geriatric population, new product developments, and favorable reimbursement scenario in developed countries are the major factors driving the growth of this market.

The report analyzes and studies the patient population affected with hernia in the US, Canada, Germany, France, the UK, Japan, China, and India. Along with patient population, the report studies the adoption of synthetic and biologic mesh in hernia repair surgeries and the adoption of suture, tack, and glue applicators for mesh fixation.

The hernia mesh segment is estimated to account for the largest share of the hernia mesh market

On the basis of product, the hernia repair market is segmented into mesh and mesh fixators. A mesh is used for reinforcing weak spots in the muscle while repairing the hernia. Mesh fixators are used to fix the mesh in its place to avoid displacement. In 2018, the hernia mesh segment is expected to account for the largest share of the market. This large share can be attributed to the higher prices of meshes compared to mesh fixators.

In 2018, tack applicators to account for the largest share of the mesh fixators market

The hernia mesh fixators market is segmented into sutures, tack applicators, and glue applicators. Among these, sutures is the most common type of mesh fixator, followed by tack. However, due to the higher price of tacks, the tack applicators segment is expected to account for the largest share in the mesh fixators market in 2018. While the rising adoption of surgical glue as mesh fixators makes glue applicators the fastest growing segment of the mesh fixators market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=203245450

In 2018, North America is projected to account for the largest market share

The global hernia repair market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (RoW). In 2018, North America is estimated to account for the largest market for hernia mesh devices. The large share of North America in this market can be attributed to the strong demand for and adoption of hernia repair in the US, presence of a large pool of hernia patients, and an efficient and favorable healthcare system are supporting the growth of the hernia mesh market in North America.

The major players in the hernia repair market profiled in this report are Covidien ( Part of Medtronic) (Ireland), Ethicon (Part of Johnson & Johnson) (US), B. Braun (Germany), C.R. Bard (Part of Becton Dickinson) (US), W. L. Gore (US), LifeCell (Part of Allergan) (Ireland), Maquet (Part of Getinge) (Sweden), Cook Medical (US), Integra (US), DIPROMED (Italy), FEG (Germany), Cousin Biotech (France), Herniamesh (Italy), Aspide Medical (France), TransEasy Medical (China), and Via Surgical (Israel).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=203245450

Global Biobanking Market Revenue, Demand, Opportunity, Segment and Key Trends 2021

According to the new market research report “Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) – Global Forecast”, published by MarketsandMarkets™, the biobanking devices market is expected to reach USD 2.69 Billion by 2022 from USD 1.85 Billion in 2017, at a CAGR of 7.8%

Regenerative medicine applications for biobanking market will drive the market;

Biobanking Market plays an integral role in advancing biomedical and translational research, through the collection and preservation of biological samples, such as blood, tissues, and nucleic acids, which are then made available for use in research to discover disease-relevant biomarkers; this is further used for diagnosis, prognosis, and predicting drug responses. Growth in the number of research activities in this segment forms a major driver for the market. The availability of government funding for regenerative medicine, stem cell therapeutics, and cell & gene therapy is supporting research activities in this segment. Apart from this, the increasing trend of cord blood banking will also aid growth of this market segment. Future prospects including advancements in orthopedic procedures with the use of stem cells are expected to further support market growth for regenerative medicine

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594

Major Biobanking Market Developments;

– In 2017, Brooks Automation, Inc. (U.S.) launched BioStore IIIv, BioStudies Biobank Data Management, FluidX, IntelliXcap Decapper systems to strengthen its product portfolio in biobanking segment.

– In 2016, Thermo Fisher Scientific Inc. (U.S.) entered into a partnership with Hamilton Storage (U.S.) to strengthened Thermo Fisher’s presence in the market.

– In 2015, Panasonic Healthcare Holdings (Japan) launched MDF-DU900V VIP -86°C Upright Freezer.

Based on region, the biobanking market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is expected to dominate the market in 2017, this is attributed to factors like increasing research activities in regenerative medicine, cell and gene therapy; growing interest in personalized medicine and biomarker discovery; increasing number of biotechnology and pharmaceutical companies; and rising investments in genomics and proteomics research in the region as compared to other regions.

Key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=594

The equipment segment is expected to dominate the biobanking devices market.

By product and service, the biobanking market is segmented into equipment, consumables, services, and software. The equipment segment is expected to dominate the global market in 2017. Rising number of biobanks and the increasing number of biospecimens are factors increasing the demand for biobanking equipment.

Blood products are estimated to command the largest biobanking devices market share.

The biobanking market is segmented by sample type into blood products, human tissues, nucleic acids, human waste products, cell lines, and biological fluids. In 2017, the blood products segment is expected to account for the largest share of the market, by sample type. Rising incidence of blood disorders and the increasing demand for various types of blood products across the globe are driving the growth of this segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=594

Global Single-cell Analysis Market 2022 - Research, Industry Trends, Supply, Sales, Demands, Analysis & Insights

According to the new market research report “Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instrument), Technique (Flow Cytometry, NGS, PCR, Microscopy, MS), Application (Research, Medical), End User (Pharma, Biotech, Hospitals) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 6.3 billion by 2026 from USD 3.1 billion in 2021, at a CAGR of 15.1% during the forecast period.

Growth Driver: Growing prevalence of cancer;

One of the most important application areas of single-cell analysis is cancer genomics. According to GLOBOCAN, the number of cancer cases will rise to approximately 30 million by 2040 from 19.3 million cases and 10 million cancer deaths in 2020. The growth in the prevalence of this disease has resulted in a need to conduct extensive research for diagnosis and treatment; single-cell analysis forms an important part of this research. The analysis of individual cells enables the correct diagnosis of diseases and monitoring of treatment efficacy. Single-cell analysis aids in the enumeration of helper T-cells, determination of DNA content, and monitoring the proliferation of tumor cells in breast cancer and other malignancies.

Recent Developments:

- In March 2021, Beckman Coulter (a subsidiary of Danaher Corporation) launched the CytoFLEX SRT Benchtop Sorter that features expanded laser and color options for use in labs of all sizes.

- In March 2020, Fluidigm Corporation (US) opened a new Center of Excellence (CoE) for Imaging Mass Cytometry (IMC) in Singapore, together with the Singapore Immunology Network (SIgN), part of the Agency for Science, Technology and Research..

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254

The Growth in the single-cell analysis market is driven by factors such as technological advancements in single-cell analysis products coupled with increasing R&D in the pharmaceutical and biotechnology industries, growing focus on personalized medicine, growth in stem cell research, and the rising prevalence of cancer.

The consumables segment accounted for the largest share of the product segment in the single-cell analysis market in 2020.

Consumables accounted for the largest share of the market in 2020. The large share of this segment can primarily be attributed to the frequent purchase of these products compared to instruments, which are considered a one-time investment. The wide applications of consumables in research and genetic exploration, exosome analysis, and isolation of RNA and DNA are also expected to drive market growth.

The research applications segment accounted for the largest share of the application segment in the market in 2020

Based on applications, the single-cell analysis market is segmented into research and medical applications. The research applications segment accounted for the largest share of the market in 2020. Increasing government initiatives in stem cell research and the wide usage of single-cell analysis in cancer research are the major factors driving the growth of the research applications segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254

The Asia Pacific region is the fastest-growing region of the market in 2020.

The market in the Asia Pacific is expected to grow at the highest CAGR of 17.4% during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in this region, rising geriatric population, rising prevalence of cancer, and increasing government initiatives.

The prominent players in the single-cell analysis market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck KGAA (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Illumina, Inc. (US), Fluidigm Corporation (US), 10X Genomics (US), and Corning Incorporated (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=171955254

Body Composition Analyzers Market - by Global In-depth Analysis, Regional Outlook, Latest Trend and Forecast

According to the new market research report “Body Composition Analyzers Market by Product (Bio-impedance analyzer/DEXA/Skinfold calipers/ADP/Hydrostatic weighing), & End-users (Hospitals/Fitness & wellness centers/Academic & Research Center/Home-users) – Analysis & Global Forecast”, published by MarketsandMarkets™, is poised to reach USD 668.16 Million, growing at a CAGR of 12.7%.

The Body composition analysis is the process to evaluate the amount of fat, muscle, and bone in the body. It gives the precise measurement of body fat in relation to lean body mass. Evaluation of body composition is essential in order to determine the risks associated with high or low levels of body fat. The growth of the overall body composition analyzers market can be contributed to rise in obese population across the globe, growing health and fitness consciousness among people, increasing government initiatives to encourage physical activity and technological advancements. In the coming years, the body composition analyzers market is expected to witness the highest growth rate in the Asia-Pacific region. North America is expected to account for the largest share of the global body composition analyzers market. However, inconsistency in the accuracy of different analyzers and high cost of equipment is likely to restrain the growth of the market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=248209133

Increasing adoption of body composition analyzers to assess the nutritional status in patients is driving the growth of this market;

Hospitals;

In hospitals, body composition analysis is majorly used for the diagnosis of osteoporosis. For this application, DEXA is utilized to measure bone density for diagnosing osteoporosis and assessing the risk of developing fractures. As a result, the growing prevalence of osteoporosis is expected to increase the adoption of DEXA in various hospitals. Moreover, various hospitals across the globe, such as the Jackson Hospital (U.S.), Ramsay Health Care (U.K.), Apollo Hospitals (India), and Elkhart General Hospital (U.S.), have now included body composition testing as a part of their patient care and wellness programs. Such developments are expected to support the growth of this end-user segment in the coming years

Fitness clubs and wellness centers;

Over the past few years, the number of fitness clubs has increased significantly as a result of the growing focus on health and fitness among people. At gyms and wellness centers, body composition analyzers not only measure the amount of body fat for weight loss but also provide complete body composition assessment to maintain health.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=248209133

The global body composition analyzers market is segmented on the basis of product type, end users and region.

Based on product, the market is segmented into bio-impedance analyzer, dual energy X-ray absorptiometry (DEXA), skin fold Calipers, air displacement plethysmography (ADP) and hydrostatic weighing. The bio-impedance analyzer is expected to account for the largest share of the body composition analyzers market, by product in 2016 and is expected to grow at highest CAGR. This large share can be attributed to the simplicity, low cost, and better accuracy as compared to other body composition analyzers.

Based on end users, the market is segmented into hospitals, fitness clubs and wellness centers, academic and research centers. In 2016, hospitals segment is estimated to account for the largest share of the body composition analyzer market, by end users in 2016 and is expected to grow at highest CAGR. The growth of this segment can be attributed to the rise in osteoporosis cases, increasing adoption of body composition analyzers to assess the nutritional status in patients and increasing health consciousness among masses.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=248209133

basis of region, the Body Composition Analyzers Market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2016, North America is expected to account for the largest share of the body composition analyzer market. Its large share can be attributed to rising obesity rates and increasing health clubs and fitness centers in the U.S. However, the Asia-Pacific market is slated to grow at the highest CAGR during the forecast period due to rising trend of overweight and obesity in China, and foothold of local players in Japan.

The major players in body composition analyzers market include InBody Co., Ltd (South Korea), Tanita Corporation (Japan), Omron Corporation (Japan), Hologic, Inc. (U.S.) and GE Healthcare (U.S.) among others.

Metabolomics Market Size, Share, Growth, Trend and Forecast

 According to the new market research report “Metabolomics Market by Product (GC,UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery, Functional Genomics), Indication (Cardiology, Oncology, Inborn Errors), End User (Academic Institute, CROs) – Global Forecast to 2025″, published by MarketsandMarkets™, the global Metabolomics Technology Market size is projected to reach USD 4.1 billion by 2025, at a CAGR of 13.4% between 2020 and 2025.

Opportunity:Biomarker development;

Metabolomics is used to identify new biomarkers through bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for developing in-vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research. As a result of these technological developments, new biomarkers are being regularly discovered. These biomarkers are required in medical sciences to better define and diagnose diseases, predict adverse drug events, and identify patient groups who would benefit from specific treatments. Moreover, in the near future, identifying biomarkers related to safety, sensitivity, and resistance to commercially available drugs will present significant growth opportunities for the metabolomics market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900

The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, growing demand for personalized medicine and increasing use of metabolomics in toxicology testing are driving the growth of the global metabolomics industry.

Separation tools accounted for the largest share in the metabolomics market in 2019.

Based on the product & service, the market is categorized into metabolomics instruments and bioinformatics tools and services. The metabolomics instruments segment is further categorized into separation tools and detection tools. Separation tools is sub segmented into gas chromatography, high-performance liquid chromatography, ultra-performance liquid chromatography, and capillary electrophoresis. Similarly, detection tools are categorized into nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and surface-based mass analysis. The separation tools segment accounted for the largest share of the market in 2019. The widespread use of separation tools in research activities, increase in funds for research projects, development of innovative technologies in these tools, and their extensive application in the drug discovery process are fueling the growth of this segment.

Cancer accounted for the largest share in the market in 2019

Based on indication, the metabolomics market has been segmented into into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications. The cancer segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the growing use of metabolomics in cancer research and increasing number of cancer patients.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=900

Academic and research institutes accounted for the largest share the metabolomics market in 2019

Based on end user, the market has been segmented into academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. The academic and research institutes segment accounted for the largest share of the market in 2019. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment.

Biomarker Discovery accounted for the largest share of the metabolomics market

Based on application, the Metabolomics Technology Market has been segmented into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and other applications. Biomarker discovery accounted for the largest share of the market in 2019. The growing implications of metabolic biomarkers to access the pathophysiological health status of patients are expected to drive market growth.

North America accounted for the largest share of the metabolomics market in 2019.

Based on the region, the global Metabolomics Technology Market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the metabolomics technologies market. The large share of the North America region can be attributed to the presence of major players operating in the market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

The metabolomics market is dominated by a few globally established players such as Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Human Metabolome Technologies, Inc. (Japan), LECO Corporation (US), Metabolon, Inc. (US), Bio-Rad Laboratories (US), Scion Instruments (US), DANI Instruments S.p.A. (Italy), GL Sciences (Japan), SRI Instruments (US), Kore Technology Ltd. (UK), and JASCO, Inc. (US) among others.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=900

Breath Analyzer Market - Emerging Industry Trends and Global Future Forecast

According to the new market research report “Breath Analyzer Market by Technology (Fuel Cell, Semicoductor Oxide Sensor, Others), End User (Law Enforcement Agencies, Enterprises, Individuals ), Application, Region (North America, Europe, APAC, RoW) – Global Forecast to 2025″, published by MarketsandMarkets™, the breathalyzers market is expected to reach USD 1,167 million by 2025 from USD 524 million in 2020, at a CAGR of 17.4% during the forecast period.

Opportunities: Technological advancements;

The breath analyzers market is technology-driven and is projected to grow at a significant rate in the coming years. Owing to the lucrative potential of the market, a number of players are focusing on developing novel technologies and are continuously introducing accurate and easy-to-use breath analyzers. In August 2019, Y Combinator, an investment company, invested in SannTek Labs to work on a new kind of breathalyzer. This breathalyzer is designed to detect blood alcohol levels as well as the type of cannabis a person has consumed in the past 3 to 4 hours.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=57484012

The Growth in the market can primarily be attributed to factors such as alcohol and drug abuse, stringent government regulations and increasing use of breath alyzers in detecting various diseases.

By technology, the fuel cell segment is expected to account for the largest share of the market in 2020

Based on technology, the breath analyzers market is segmented into fuel cells, semiconductor oxide sensors, and other technologies (infrared spectroscopy and chemical crystals). In 2020, the fuel cells segment accounted for the largest share of the global market. Fuel cells are the most widely used technology in breath analyzers. Fuel cell-based breath analyzers offer an extremely high level of accuracy, sensitivity, and reliability. They are specifically tuned to detect alcohol and do not require multiple sensors. These analyzers are considered the gold standard of handheld alcohol testers for both personal and professional use.

By application, the alcohol detection segment is expected to account for the largest share of the market in 2020

On the basis of application, the breath analyzers market is segmented into alcohol detection, drug abuse detection, and medical applications. The alcohol detection segment accounted for the largest market share in 2020. This segment is also projected to register the highest CAGR during the forecast period. The growth of this segment is primarily driven by stringent government regulations for driving under the influence (DUI).

By end user, the law enforcement agencies segment is expected to account for the largest share of the breath analyzer market in 2020

Based on end users, the breathalyzers market segmented into law enforcement agencies, enterprises, and individuals. In 2020, the law enforcement agencies segment accounted for the largest share of the global market. Stringent safety laws against DUI and the rising scale of screening and evidential testing are driving the adoption of breath analyzers in law enforcement.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=57484012

Asia-Pacific to witness the highest growth rate in 2020

Based on region, the breath analyzer market is segmented into North America, Asia-Pacific, Europe and Rest of the world (RoW). Asia Pacific is expected to register the highest CAGR during the forecast period. The major factors driving the growth of the Asia Pacific market include as growing consumption of alcohol, increasing research on the medical applications of breath analyzers, and the development of advanced breath analyzers.

The prominent players in the global breath analyzer market include Drägerwerk AG & Co. KGaA (Germany),  MPD, Inc (US), Lifeloc Technologies (US), BACtrack, Inc. (US), Quest Products, Inc. (US), Akers Biosciences, Inc. (US), Intoximeter, Inc. (US), AK GlobalTech Corporation (US), Alcohol Countermeasure Systems Corporation (Canada), EnviteC-Wismar GmbH (Germany), Lion Laboratories Ltd. (UK)

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=57484012

Artificial Cornea and Corneal Implant Market - Global Industry Leaders & Growth Strategies Adopted

According to the new market research report “Artificial Cornea Implant Market by Type (Human Cornea, Artificial Cornea), Transplant Type (Penetrating Keratoplasty, Endothelial Keratoplasty), Disease Indication, End Users (Hospitals, Specialty Clinics & ASCs) – Global Forecast to 2026″, published by MarketsandMarkets™, the global Artificial Cornea Implant Market is projected to reach USD 599 million by 2026 from USD 418 million in 2021, at a CAGR of 7.4% from 2021 to 2026.

Opportunity: Shortage of corneal donors;

There is a significant requirement of corneal donors across the globe, as approximately 10 million people are in need of corneal transplants. Densely populated counties such as India suffer from a significant shortage of donor corneas, and there is a waiting period of more than six months for corneal transplants among patients suffering from corneal blindness. Approximately 6.8 million people in the country have poor vision in one eye, and nearly one million people have poor vision in both eyes due to corneal disorders. It was estimated that by the end of 2020, India would suffer from 10.6 million cases of unilateral corneal blindness. In 2019, around 120,000 people were affected by corneal blindness. Around 250,000 corneas are needed annually in the country; however, the total number of corneas donated each year is around 25,000. The high burden of corneal blindness, coupled with a shortage of corneal donors, is expected to offer high-growth opportunities to manufacturers of corneal implants.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182165973

The Corneal Implant Market growth is largely driven by the The growing geriatric population and the rising prevalence of eye diseases are the major drivers for the artificial cornea and corneal implants market. The increasing prevalence of eye disorders and government initiatives to control visual impairment are further boosting the market growth.

The artificial cornea segment is projected to witness fastest growth during the forecast period

On the basis of type, the artificial cornea and corneal implants market is segmented into human cornea and artificial cornea. The artificial cornea segment is projected to witness fastest growth during the forecast period. An artificial corneal transplant, also known as keratoprosthesis (KPro), enables the restoration of vision in conditions wherein the cornea and the eye surface is affected or damaged. The scarcity of human eye donors has resulted in the development of innovative solutions such as artificial corneas. Additionally, individuals with a history of multiple previous graft failures, Stevens-Johnson syndrome, chemical burns, severe dry eyes, congenital aniridia, or limbal stem cell deficiency are indications for KPro. One of the commonly used keratoprosthesis is Boston Keratoprosthesis (Boston KPro). To date, over 15,000 Boston KPro have been implanted across the globe.

Penetrating keratoplasty segment accounted for the largest share of artificial corneal implant market in 2020.

On the basis of transplant type, the Artificial Cornea Implant Market is segmented into penetrating keratoplasty, endothelial keratoplasty, and other transplants (including anterior lamellar keratoplasty (ALK) and keratoprosthesis). In 2020, the penetrating keratoplasty segment accounted for the largest share of the global artificial cornea and corneal implants market. The large share of this segment can be attributed to the rising number of people suffering from eye disorders such as infectious keratitis and injury of the eyeball.

In 2020, Fuchs’ dystrophy segment accounted for the largest share of artificial cornea market

On the basis of disease indication, the corneal implants market is segmented into fungal keratitis, Fuchs’ dystrophy, keratoconus, and other diseases. In 2020, the Fuchs’ dystrophy segment accounted for the largest share of artificial cornea and corneal implant market. The rising incidence of the disease and the growing awareness among people regarding early disease diagnosis are the key factors driving the growth of this segment.

In 2020, hospitals segment accounted for the largest share of corneal implant market

Based on end users, the artificial cornea and corneal implants market is segmented into hospitals and specialty clinics and ambulatory surgery centers (ASCs). In 2020, hospitals segment accounted for the largest share of artificial corneal implant market. The rising prevalence of eye disorders, growth in the geriatric population, increasing awareness about the innovative artificial corneal technology, the willingness of patients to spend more on advanced treatments, and the growing number of hospitals in developing countries such as India, China, and Brazil are some of the key factors driving the growth of the artificial cornea and corneal implants market for hospitals.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=182165973

Asia Pacific is expected to witness fastest growth during the forecast period of 2021–2026.

Geographically, the artificial cornea and corneal implant market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to witness highest CAGR during the forecast period of 2021–2026. The Asia Pacific forms the most lucrative region in the artificial cornea and corneal implants market, owing to the large population in countries such as China and India, rapid growth in the geriatric population, improving healthcare infrastructure, growing per capita income, and the rising focus of key market players on this region.

The prominent players in artificial cornea implant market are AJL Ophthalmic (Spain), CorneaGen Inc. (US), Addition Technology, Inc. (US), LinkoCare Life Sciences AB (Sweden), Presbia plc (Ireland), Mediphacos (Brazil), Aurolab (India), Cornea Biosciences (US), DIOPTEX GmbH (Austria), EyeYon Medical (Israel), Massachusetts Eye and Ear (US), Florida Lions Eye Bank (US), SightLife (US), Advancing Sight Network (US), San Diego Eye Bank (US) and L V Prasad Eye Institute (LVPEI, India).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=182165973